

Ontario Public Drug Programs

Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs

March 16, 2017

Through the Pan-Canadian Select Molecule Price Initiative for Generic Drugs, (formerly known as the Pan-Canadian Competitive Value Price Initiative for Generic Drugs), jurisdictions work together to lower generic drug prices for public drug plans.

Since 2013, this Initiative has successfully negotiated lower drug prices for 17 high expenditure molecules in Ontario to 18% of the brand price.

Effective April 1, 2017, the following six generic molecules will be reduced to 15% of the brand price for one year:

- Amlodipine
- Atorvastatin
- Clopidogrel
- Pantoprazole Sodium
- Ramipril
- Simvastatin

In Ontario, the prices of 11 of these 17 molecules will remain at 18% of the brand price for one more year. They include:

- Citalopram
- Donepezil
- Ezetimibe
- Gabapentin

- Metformin
- Olanzapine
- Omeprazole
- Quetiapine
- Rabeprazole
- Rosuvastatin
- Venlafaxine

The Ministry of Health and Long-Term Care has posted a new file ([Edition no. 42, Summary of Changes – April 1, 2017](#)) with these listing changes.

We appreciate your continued cooperation in making these benefit adjustments.